SYNOPSIS 5-Fluorocytosine (5 FC) showed marked in vitro activity against nearly all the clinical isolates of Candida and Cryptococcus examined; the required minimal inhibitory concentration was usually below 2 ,tg/ml and the minimal cidal concentration below 10 ,ug/ml. The drug had limited activity towards Aspergillus species and dermatophytes. Strains of Candida and other fungi with greatly enhanced resistance were fairly readily obtained by successive cultures on increasingly high concentrations of 5-fluorocytosine.
A serious gap has recently become increasingly apparent in our antimicrobial armoury; a wide range of drugs is now used for the safe and effective treatment of almost all bacterial disease, but only one agent, amphotericin B, has hitherto been available for systemic antimycotic therapy. The toxic hazards of this polyene are considerable and it must be used with great care. The lack of safe systemic antimycotic drugs has been emphasized after therapy with potent antibacterial and immunosuppressive agents after organ transplants, and after the use of cytotoxic drugs in leukaemia. Many of these cases ultimately suffer an overwhelming generalized mycotic infection, frequently by fungi normally regarded as feebly pathogenic or not-pathogenic. Extensive reconstructive surgery, particularly when artificial internal prostheses are implanted (Holt, 1969) , carries similar risks of complication.
The emergence of new systemic antimycotic agents has therefore aroused great interest; 5-fluorocytosine (5 FC) became available in the early Received for publication 28 December 1972 . 'Dr Newman died after this paper had been wriUen.
1960s when it was synthesized in the laboratories of Roche at Basel as an antimetabolite for cytosine during a search for antileukaemic drugs. In this it proved ineffective, but Grunberg, Titsworth, and Bennett (1964) showed that it was active in the control of mouse candidaemia; by the end of the decade it had been used to treat many cases ofsevere candidosis and cryptococcosis (Utz, Tynes, Shadomy, Duma, Kannan, and Mason, 1969; Record, Skinner, Sleight, and Speller, 1971; Davies and Reeves, 1971 ; and many others). The mode of action of 5-fluorocytosine has been studied extensively; at first it was suggested that the compound competed with its analogue cytosine, or with related pyrimidines, which were regarded as essential metabolites for sensitive fungal cells, but not for bacteria or mammalian cells (fig 1) . Scholer (1968) 5-fluorouracil, which is then incorporated into their t-RNA. Up to 50 % of t-RNA uracil may be replaced by 5-fluorouracil, with inhibitory effect. Whichever hypothesis is accurate, it seems certain that all experiments in vitro with 5-fluorocytosine must be performed with cytosine-free media (Shadomy, 1969) ; the use of standard bacteriological or mycological media containing the free amino acid invariably gives highly fallacious results in which the drug appears to be relatively inactive against fungi. Furthermore, fungi previously grown in standard media should first be subcultured in cytosine-free medium before subjecting them to sensitivity tests, so that the organisms become depleted of cytosine; washing by suspension and centrifugation in sterile buffer solution may not be sufficient. Shadomy explained the activity of 5 FC in serum and other biological fluids by assuming that these complex mixtures of natural undegraded proteins contain no free cytosine, a suggestion that we have confirmed by chromatographic analysis.
Methods

SOLUTIONS OF 5 FC
A white, finely crystalline powder, 5 FC was dissolved at 1 % (10 000 ,tg/ml) in 0-9 % sterile aqueous saline at pH 6-5; this followed the procedure of Shadomy (1969) . One ml aliquots of this stock solution were stored at -20°, where tests showed no loss of activity after six months. Appropriate dilutions were made in 0-01M phosphate buffer at pH 7 0.
CLINICAL ISOLATES
Candida and fungi were isolated from clinical specimens by the methods reported elsewhere (Holt and Newman, 1967 By discs containing 1, 10, and 100 ,tg 5 FC Filter paper discs, 9 mm, were impregnated with 5 FC solution and rapidly vacuum dried. The discs were presterilized in dry air at 1600 for one hr; dilutions of 5 FC were made in 0-01 M phosphate buffer at pH 7-2 to contain 30, 300, and 3000 ,ug/ml. Discs of the required strength were prepared by placing one drop from a 30 drop/ml pipette onto the appropriate paper, which was immediately vacuum dried at room temperature over silica gel. The dry discs were
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The fungus to be tested was grown overnight in yeast nitrogen base broth; in this and all other subculture prodecures used in these studies every care was taken when removing fungi from normal culture media presumed to contain free cytosine to ensure that a minimum of the medium was carried over into cytosine-free cultures. The overnight yeast nitrogen base broth culture was diluted in yeast nitrogen base broth containing 0 1 % of a nonionic surfactant (TritonXlOO) to a densityof approximately 1 x 105 cells per ml for candida or cryptococci; this was impossible with mycelating fungi, so 1/100 dilutions of very well mixed overnight cultures were made. An even lawn of dilute suspension was sown over yeast nitrogen base agar or Czapek Dox plates and allowed to dry for one hour. Discs containing the three concentrations of 5 FC were placed on the agar surface and the plates incubated for 48 hours. Organisms giving zones of inhibition greater than 20 mm diameter round the 1 Kg discs were recorded as fully sensitive; zones between 14 and 18 mm diameter round the 10 ,ug disc were regarded as resistant to the drug.
Because of our interest in the emergence of strains relatively resistant to 5 FC, all sensitivity plates were carefully scrutinized for a minority of colonies growing in the zone of inhibition near the disc; most plates were therefore kept for four to five days before being discarded.
By liquid tests: the estimation of minimal inhibitory and cidal concentrations (MIC and MCC) All estimations and assays were carried out at pH 7-0 and at 370 to simulate biological conditions.
Concentrations of 5 FC in the range 0-05-50 jug/ml were made in 2 ml tubes of yeast nitrogen base broth together with a broth tube without drug. Inocula of Candida and other yeast-like organisms were added to give a final initial concentration of about 1 x 10O cells/ml; mycelating fungi were added as a very light inoculum. All cultures were thoroughly mixed and incubated for 48 hr, after which the MIC was noted by visible turbidity. Standard loop subcultures from each tube were made onto standard infusion broth agar plates, which were incubated for 24 to 48 hr and the MCC recorded by visible growth. This medium contained cytosine, which effectively antagonizes the antimycotic action of 5 FC, thus fulfilling one of the desirable conditions for the test because it is possible to neutralize the inhibitory action of the drug carried over from the first stage. With many antimicrobial agents it is difficult to meet this requirement.
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The agar dilution technique was also used to estimate sensitivity to 5 FC; light inocula of fungi were spotted onto yeast nitrogen base agar plates containing a range of drug concentrations; the MIC was read after 48 hours' incubation and the MCC by subsequent velvet pad replication onto drug-free infusion agar. Results from liquid tests compared well with the agar dilution readings.
Induction of Resistant Mutants
Very light inocula of fungi were successively passaged across increasing drug gradients on yeast nitrogen base agar plates (Szybalski, 1952) , usually starting with plates having a gradient 0-02 ug/ml 5 FC. Each series of plates was given 48-72 hours' incubation for a sequence of 20 passages, and the initial liquid MIC of each strain was compared with the final liquid MIC.
Assay of 5 FC in Biological Fluids
Shadomy (1969) used a saccharomyces sp. (S. cerevisiae ATCC 9763) as indicator organism in plate bioassays, and found the lower limit of sensitivity of his method to be about 0-4 jug/ml. We tested this strain and many other strains of Saccharomyces and Candida, and eventually selected a strain of C. albicans (Carshalton 2606) for routine assays; this readily detected 0-1 jg/ml 5 FC. The indicator organism used by us for clotrimazole assays, C. pseudotropicalis Carshalton, had a similar level of sensitivity to 5 FC.
The assay strain was maintained in yeast nitrogen base broth by daily subcultures and on each occasion a plate-out was included to check purity. Base layers of 50 ml of 1 % ion agar were poured into 14 cm polystyrene plates and after setting they were overlaid with 20 ml of yeast-nitrogen base agar seeded with 0-1 ml of overnight indicator-organism culture; the plates were thoroughly dried at 370. Larger square assay plates, 25 x 25 cm, were also used, with 200 ml base and 80 ml overlay.
The range of standards was 0-1, 0 5, 2-0, and 10 pLg/ml 5 FC prepared in 0-01 M buffer at pH 7 0.
Earlier studies had confirmed the observation of Davies and Reeves (1971) that zone diameters for 5 FC in serum were the same as those in aqueous solution, and the latter were therefore used for bioassays of all biological fluids. These were diluted in buffer to final levels of 5 FC within the standard range; sera were diluted 1/5 or 1/10, and urines usually 1/100. Diluted fluids and standards were applied to the agar surface in fish-spine bead reservoirs (Lightbown and Sulitzeau, 1957) Fresh specimens of urine were examined at least once a day throughout treatment and for several weeks after the drug was stopped. General clinical improvement, complete absence of viable Candida, and marked diminution of the pus cell count in several successive specimens were required before therapy was stopped. Assessment of complicated cases such as these is notoriously difficult, and bacterial infection sometimes obscured the picture.
ADMINISTRATION OF DRUG
On most occasions adults received tablets containing 0-5 g 5 FC at six or eight hourly intervals to a total of 100 mg/kg/day. The tablets were unsuitable for infants, who were given an aqueous suspension of crushed tablets containing the calculated six hourly dose in 1 or 2 ml. Gum tragacanth (0l2 %) was added to the suspension, which was stored at 4°C; assays revealed that it remained stable for three months under these conditions, although no more than 14 days' supply was issued at a time to the wards. DOSAGE Our first cases were given 100 mg/kg/day 5 FC as an oral suspension in four six-hourly doses per day. It was soon found that serum levels over 20 ,Lg/ml and urine levels well above 200 ,tg/ml resulted from this dose; in later cases, therefore, the dose was successively reduced after about a week to 50 mg/kg/day and then to 25 mg/kg/day for the remainder of the course, providing that assays revealed satisfactory levels. None of our patients showed any side effects attributable to the drug. ,ug/ml were used because it was estimated that the body fluid concentrations of this compound would probably be in that range. Cytosine arabinoside alone up to 100 ,ug/ml was found to have no inhibitory action on the Cr. neoformans. At a concentration of 1 ,ug/ml both cytosine and cytosine arabinoside reduced the activity of 5 FC at least one hundredfold. There appeared to be no such interference by procarbazine (Natulan, Roche) at concentrations up to 20 jig/ml in a similar experiment, and the patient later received this drug.
Discussion
The activity in vitro of 5-fluorocytosine is confined largely to yeast-like genera, principally Candida and Cryptococcus, and we confirm the observations of Shadomy (1969) that the drug has only limited activity against Aspergillus spp (table I). In the case of Candida, fungistatic and fungicidal concentrations were almost always in the range of 0-2 to 2 /Lg/ml and 2 to 50 ,ug/ml respectively, and corresponding values of 0-2 to 2 jg/ml and 0-2 to 10 ,ug/ml were found for a few fresh clinical isolates of Cr. (Holt and Newman, 1972a) , and that it may often be a mistake to regard a culture as homogenous in its drug sensitivity. The serum and urine 5 FC levels in all the patients reported here exceeded the fungal MIC/MCC values at the beginning of treatment (table III). The first cerebrospinal fluid level (34 Htg/ml) in the patient with cryptococcal meningitis was very much the same as his serum level (26 ,ug/ml), both taken some five hours after an oral dose of 1-5 g (table IV) . This suggests that the small molecule diffuses easily through body barriers and that therapeutic levels would be found in sputa of patients receiving the drug for pulmonary mycoses; no such specimens have yet passed through our hands. The second cerebrospinal fluid level was much lower and coincided with the intrathecal use of cytosine arabinoside; tests in vitro clearly showed that this agent antagonized the inhibitory action of 5 FC against the patient's strain of Cr. neoformans, probably acting in the same way as cytosine.
We were unable to record a coherent series of serum assays to demonstrate peak levels after an oral dose; the adult patients in other hospitals were not accessible to us and the small infants in this hospital were too sick for frequent blood sampling. Our impression is that the peak serum level occurred between one and two hours after a dose, and we tried wherever possible to sample blood at two and six hours. The faeces assayed were all from infants; failure to demonstrate active antimycotic activity in any may have been due to one or more of several causes: technical inadequacy of the extraction process, total absorption of the drug, destruction or conjugation to inactive derivatives are all possible reasons.
A clear warning was sounded by Shadomy (1969) when he noted that resistant strains of Candida and Cryptococci occasionallly emerged during therapy, an observation reinforced in our minds when we found that members of these genera could readily be trained in vitro to very high levels of 5 FC resistance (table V) . From the start of our therapeutic studies with the drug a careful watch was therefore kept both for infecting fungi with a minority population of greater resistance than the majority and for emergent resistant strains. For a long time none was seen, but during the past few months we have investigated three instances. In the first, reported by Cartwright, Shaldon, and Hall (1972) , the sensitivity of C. albicans in the urine of a man receiving 5 FC for urinary candidosis after renal transplantation escalated from 0-25 ,ug/ml to more than 1000 jig/ml during six days' treatment. The cultures were kindly referred to us at an early stage, and our impression was that the pretreatment culture contained a minority population of 5 FC-resistant cells, which rapidly emerged despite adequate urine and serum drug levels; in our hands both sensitive and resistant isolates were sensitive to clotrimazole, with which this patient was successfully treated. The second case was no. 4 in our series, where the strain of C. albicans was initially homogenous and fully sensitive to 5 FC (MIC 0 05 ,ug/ml, MCC 1 ,ug/ml). After 20 weeks' treatment, during which high serum and urine drug levels were maintained, C. albicans reappeared in the urine, apparently identical to the pretreatment (Logan and Goldberg, 1972 (Holt, 1970; Holt and Newman, 1972b) and an almost infinite range of derivatives is possible, with widely differing pharmacological properties. Although recent experiences with 5 FC have naturally led us to temper our earlier optimism, its success in seven of our eight cases leaves us with little doubt of its potential. Providing searching studies in vitro are continued for emergent resistance in each subject treated, the drug will take a valuable share in meeting the ever-increasing demand for systemic antimycotic agents.
